Paragon 28's stock has seen a significant recovery from its low point of $4.89 in the third quarter of 2024, with InvestingPro data showing an impressive six-month return of 38.4%.

M VM Partners, LLC, a significant stakeholder in Paragon 28, Inc. (NASDAQ:FNA), disclosed the sale of 111,465 shares of common stock, valued at approximately $1.32 million. The transactions ...

Shares of Paragon 28, Inc. (NYSE:FNA – Get Free Report) have received a consensus rating of “Hold” from the six brokerages that are presently covering the firm, Marketbeat reports.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. for $13.00 per share in ...

ENGLEWOOD, Colo., March 24, 2025--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to ...

The Ademi Firm is investigating Paragon 28 (NYSE: FNA) for possible breaches of fiduciary duty and other violations of law in its transaction with Zimmer Biomet .

ENGLEWOOD, Colo., March 07, 2025--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to ...

Paragon 28 had a negative net margin of 25.31% and a negative return on equity of 37.90%. The company had revenue of $71.75 million during the quarter, compared to the consensus estimate of $70.81 ...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American College of Foot ...